Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad2/MART-1v2 and Ad2/gp100v2 Vaccines in Melanoma
NCT00010309Phase 2Unknown
- Sponsor
- Sanofi
- Start
- Nov 2000
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of Ad2/MART-1v2 and gp100v2 in melanoma (3 arms), sponsored by Sanofi. Primary endpoints: Safety of vaccines and Maximum Tolerated Dose. Status: unknown.
02
Drugs
Ad2/MART-1v2gp100v2
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00010309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010309.